Aposense Squeezes Onto Public Markets with $24 M Israeli Offering
This article was originally published in The Pink Sheet Daily
Executive Summary
With help from Teva, the Israeli biotech aims to turn its apoptosis-targeting platform into imaging and therapeutic products.